NEWS: Industry attendance at ECRD2020 - Who should register?
The European Conference on Rare Diseases & Orphan Products (ECRD) is an opportunity for industry to come together with patients to discuss the state-of-the-art in rare disease policy, research, diagnosis, treatment and care.
#ECRD2020 takes place uniquely online via an interactive online platform on 14 and 15 May and it is recognised globally as the largest, patient-led rare disease event.
Together, we are empowering the rare disease community to drive change where it is most needed and shaping the future for people living with a rare disease!
Which sectors should attend ECRD 2020
- Biotech, biopharma, pharma;
- Equipment, tools, software;
- Medical device manufacturers;
- Executive search firms;
- Market Access experts;
- Law Firms/Patent Firms…
What to expect when attending ECRD 2020
- High visibility among all stakeholders in the rare disease field;
- Respected forum for presenting policy-related topics;
- Connect with key decision-makers;
- Increased recognition for you and your organisation amongst thought leaders in the rare disease field;
- Largest patient-led conference of its kind;
- Online exhibition and networking spaces;
- And much more…
A unique opportunity
ECRD’s 2020 theme “The journey of living with a rare disease in 2030” recognises that the next decade holds great potential for improvement, we all have a role to play in preparing for it. Tremendous progress has been made by the rare disease community, but vigilance and constant effort is necessary if we wish to hold on to important gains.
The health of 30 million people living with a rare disease in Europe should not be left to luck or chance. As the EU plans its future expenditure, ECRD 2020 serves as an opportunity to press the “pause button” and consider what policies we need to put in place today to prepare for a better patient journey in 2030 and beyond.
The dialogue, learning and conversations that take place during the Conference form part of the groundwork that will shape current and future rare disease policies and allow for important and innovative discussions on a national and an international level to take place.
Why attend ECRD 2020 online?
- Hear directly from patients and patient organisations. 50% of conference attendees in 2018 were affiliated to patient organisations and EURORDIS ensures that the perspectives and questions of people living with a rare disease and their organisations inform the conservation.
- Inspire and be inspired by concrete practices that healthcare companies implement to enable a patient-centric approach to therapeutic development.
- Dialogue with all of the stakeholders shaping your environment: patient advocates, policy makers, regulators, member state representatives, academia, researchers, clinicians, HTA evaluators, payer bodies and industry colleagues.
- See the full picture of how different elements are coming together at global, regional and country level to support orphan medicinal products discovery, development and access.
about the latest advances, challenges, facts, figures and trends in the field of rare diseases with over 100 expert speakers.
SHAPE THE FUTURE
of rare diseases alongside patient advocates, policy-makers, healthcare industry representatives, clinicians, payers, regulators and Member State representatives
SHOWCASE YOUR WORK
to all stakeholders of the rare disease community.
ECRD welcomes all stakeholders
With over 850 stakeholders from 58 countries attending the previous ECRD in 2018, the conference has seen the number of participants and its impact magnify each year since the first meeting in 2001. Working in synergy with national and regional initiatives, the ECRD enhances the efforts of all stakeholders, and encourages collaboration to promote an equal quality of care and access to treatment for patients across Europe.
Dialogue with all of the stakeholders shaping your environment: patient advocates, policy makers, regulators, member state representatives, academia, researchers, clinicians, HTA evaluators, payer bodies and industry colleagues.
See the full picture of how different elements are coming together at global, regional and country level to support orphan medicinal products discovery, development and access.